Ueda Masako, Dunbar Richard L, Wolska Anna, Sikora Tracey U, Escobar Maria Del Rosario, Seliktar Naomi, deGoma Emil, DerOhannessian Stephanie, Morrell Linda, McIntyre Adam D, Burke Frances, Sviridov Denis, Amar Marcelo, Shamburek Robert D, Freeman Lita, Hegele Robert A, Remaley Alan T, Rader Daniel J
Division of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania 19104.
Lipoprotein Metabolism Section, Cardio-Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20894.
J Clin Endocrinol Metab. 2017 May 1;102(5):1454-1457. doi: 10.1210/jc.2016-3903.
Familial chylomicronemia syndrome (FCS) is a rare heritable disorder associated with severe hypertriglyceridemia and recurrent pancreatitis. Lipoprotein lipase deficiency and apolipoprotein C-II deficiency are two well-characterized autosomal recessive causes of FCS, and three other genes have been described to cause FCS. Because therapeutic approaches can vary according to the underlying etiology, it is important to establish the molecular etiology of FCS.
A man originally from North Africa was referred to the University of Pennsylvania Lipid Clinic for severe hypertriglyceridemia and recurrent pancreatitis, consistent with the clinical diagnosis of FCS. Molecular analyses of FCS-associated genes revealed a homozygous missense variant R72T in APOC2. Molecular modeling of the variant predicted that the apolipoprotein C-II R72T peptide has reduced lipid binding affinity. In vitro studies of the patient's plasma confirmed the lack of functional apoC-II activity. Moreover, the apoC-II protein was undetectable in the patient's plasma, quantitatively as well as qualitatively.
We identified a missense APOC2 variant causing apoC-II deficiency in a patient with severe hypertriglyceridemia and recurrent pancreatitis. Beyond dietary management and usual pharmacologic therapies, an apoC-II mimetic peptide may become an optional therapy in patients with apoC-II deficiency in the future.
家族性乳糜微粒血症综合征(FCS)是一种罕见的遗传性疾病,与严重的高甘油三酯血症和复发性胰腺炎相关。脂蛋白脂肪酶缺乏症和载脂蛋白C-II缺乏症是FCS的两种已明确的常染色体隐性病因,另外还有三个基因被描述可导致FCS。由于治疗方法可能因潜在病因而异,因此确定FCS的分子病因很重要。
一名来自北非的男子因严重的高甘油三酯血症和复发性胰腺炎被转诊至宾夕法尼亚大学脂质诊所,符合FCS的临床诊断。对FCS相关基因的分子分析显示,APOC2基因存在纯合错义变异R72T。该变异的分子模型预测,载脂蛋白C-II R72T肽的脂质结合亲和力降低。对患者血浆的体外研究证实缺乏功能性载脂蛋白C-II活性。此外,在患者血浆中,无论是定量还是定性都检测不到载脂蛋白C-II蛋白。
我们在一名患有严重高甘油三酯血症和复发性胰腺炎的患者中鉴定出一种导致载脂蛋白C-II缺乏的错义APOC2变异。除了饮食管理和常规药物治疗外,载脂蛋白C-II模拟肽未来可能成为载脂蛋白C-II缺乏患者的一种可选治疗方法。